View details of this raise on Seedstage

Brooklyn, NY

Developing a wearable brain stimulation device for mental health and performance.

• Wearable Brain Stimulation: Fisher Wallace Labs has developed a wearable device that targets mood, sleep, and cognitive resilience.
• FDA Clearance Pending: The company is awaiting FDA clearance for its device to treat anxiety, depression, and insomnia.
• Collaborative Research: Research partners include the U.S. Department of Veterans Affairs and Harvard Medical School.
• Business Model: The company focuses on high-margin, scalable hardware with a smartphone-like upgrade cycle.
• Focus on Veterans: The device is being tested within the U.S. Department of Veterans Affairs, focusing on veterans and first responders.

Fisher Wallace Labs is advancing its neurotechnology to enhance mental health and high performance. The company has developed a wearable brain stimulation device, OAK, which targets mood, sleep, autonomic function, and cognitive resilience. This device has been validated in treating anxiety, depression, and insomnia, and is pending FDA clearance. Fisher Wallace Labs is collaborating with institutions such as the U.S. Department of Veterans Affairs and Harvard Medical School to further its research and development. The company aims to use the funds raised to complete the development of OAK, manufacture inventory, hire key talent, and market the device to government, employer, and consumer channels.

Fisher Wallace Labs has a business model centered on high-margin, scalable hardware with a smartphone-like upgrade cycle. The company is also developing digital products and services to complement its hardware. With a strong track record of sales under temporary FDA clearance, Fisher Wallace Labs is preparing to launch its first fully realized product. The company is focused on expanding its reach through government procurement and insurance reimbursement pathways, leveraging its large-scale clinical evidence and institutional partnerships. The device is currently being tested within the U.S. Department of Veterans Affairs, with a focus on veterans, warfighters, and first responders.

Company Info

Fisher Wallace develops wearable brain stimulation devices for mental health and cognitive performance enhancement.

Fisher Wallace develops wearable brain stimulation technology aimed at improving mental health and cognitive performance. Their devices are designed to engage brain structures that influence mood, sleep, and autonomic functions, and have been validated for treating conditions such as anxiety, depression, and insomnia. The company collaborates with institutions like the U.S. Department of Veterans Affairs and Harvard Medical School to conduct clinical trials and real-world studies, supporting their FDA clearance applications.

The business model focuses on high-margin, scalable hardware with a smartphone-like upgrade cycle, targeting government, enterprise, and consumer markets. Fisher Wallace is preparing to launch its next-generation product, OAK, which integrates advanced sensors for brain activity monitoring. The company has a strong track record of sales and user engagement, with over 60,000 active users and 14,000 prescribers of their proof-of-concept device.